Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study ; volume:13 ; number:2 ; day:15 ; month:2 ; year:2024 ; pages:465-473 ; date:4.2024
Neurology and Therapy ; 13, Heft 2 (15.2.2024), 465-473, 4.2024
- Urheber
-
Alsaadi, Taoufik
Suliman, Reem
Santos, Vanessa
Qaisi, Ibrahim Al
Carmina, Princess
Aldaher, Batool
Haddad, Shadi
Bader, Yazan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40120-024-00586-w
- URN
-
urn:nbn:de:101:1-2405211139575.958346078644
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Alsaadi, Taoufik
- Suliman, Reem
- Santos, Vanessa
- Qaisi, Ibrahim Al
- Carmina, Princess
- Aldaher, Batool
- Haddad, Shadi
- Bader, Yazan
- SpringerLink (Online service)
Ähnliche Objekte (12)
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study
Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor : Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study
Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor : Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study
Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine